MA38493A1 - Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane - Google Patents

Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane

Info

Publication number
MA38493A1
MA38493A1 MA38493A MA38493A MA38493A1 MA 38493 A1 MA38493 A1 MA 38493A1 MA 38493 A MA38493 A MA 38493A MA 38493 A MA38493 A MA 38493A MA 38493 A1 MA38493 A1 MA 38493A1
Authority
MA
Morocco
Prior art keywords
tryptophan
treat
immunosuppression
inhibitors
metabolism
Prior art date
Application number
MA38493A
Other languages
English (en)
Other versions
MA38493B1 (fr
Inventor
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Mario Mautino
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50686105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of MA38493A1 publication Critical patent/MA38493A1/fr
Publication of MA38493B1 publication Critical patent/MA38493B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des inhibiteurs d'ido et de tdo et des compositions pharmaceutiques les comprenant, qui peuvent être utilisés pour moduler une activité de l'indoleamine 2,3-dioxygénase et de la tryptophane 2,3 dioxygénase ; traiter l'immunosuppression ; traiter des états pathologiques qui sont améliorés par inhibition de la dégradation du tryptophane ; augmenter l'efficacité d'un traitement anticancéreux qui consiste à administrer un agent anticancéreux ; traiter l'immunosuppression spécifique d'une tumeur associée à un cancer ; et traiter l'immunosuppression associée à une maladie infectieuse.
MA38493A 2013-03-14 2014-03-10 Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane MA38493B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
PCT/US2014/022680 WO2014159248A1 (fr) 2013-03-14 2014-03-10 Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane

Publications (2)

Publication Number Publication Date
MA38493A1 true MA38493A1 (fr) 2017-02-28
MA38493B1 MA38493B1 (fr) 2017-10-31

Family

ID=50686105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38493A MA38493B1 (fr) 2013-03-14 2014-03-10 Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane

Country Status (22)

Country Link
US (2) US9617272B2 (fr)
EP (2) EP3366678A1 (fr)
JP (2) JP6093903B2 (fr)
KR (1) KR20150126623A (fr)
CN (1) CN105189466A (fr)
AU (2) AU2014241079C1 (fr)
BR (1) BR112015022588A2 (fr)
CA (1) CA2902174A1 (fr)
CL (2) CL2015002649A1 (fr)
CR (1) CR20150485A (fr)
HK (1) HK1213259A1 (fr)
IL (1) IL241027A0 (fr)
MA (1) MA38493B1 (fr)
MX (1) MX361375B (fr)
PE (1) PE20151593A1 (fr)
PH (1) PH12015501866A1 (fr)
RU (1) RU2667509C2 (fr)
SA (1) SA515361127B1 (fr)
SG (2) SG10201707545XA (fr)
UA (1) UA118103C2 (fr)
WO (1) WO2014159248A1 (fr)
ZA (1) ZA201607948B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (fr) 2011-04-15 2018-03-17
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
CN107074859B (zh) 2014-09-05 2021-08-06 默克专利有限公司 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
AU2015341913B2 (en) * 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
WO2016100851A1 (fr) 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Procédés et compositions pour le traitement de la rétinopathie et d'autres maladies oculaires
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN107531693B (zh) * 2015-04-10 2021-07-06 百济神州有限公司 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
WO2016165613A1 (fr) 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Hétérocycles utiles comme inhibiteurs d'ido et de tdo
WO2016186967A1 (fr) * 2015-05-15 2016-11-24 Gilead Sciences, Inc. Composés de carboxymidamide de benzimidazole et d'imadazopyridine présentant une activité en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
WO2017107979A1 (fr) 2015-12-24 2017-06-29 Genentech, Inc. Inhibiteurs de tdo2
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
SG11201806480UA (en) 2016-02-02 2018-08-30 Emcure Pharmaceuticals Ltd Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CA3015012A1 (fr) * 2016-02-19 2017-08-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compose tricyclique servant d'immunomodulateur
WO2017140272A1 (fr) * 2016-02-19 2017-08-24 正大天晴药业集团股份有限公司 Composé tricyclique servant d'immunomodulateur
WO2017149469A1 (fr) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Composés hétérocycliques utiles en tant que modulateurs de l'ido et/ou de la tdo
MX2018013164A (es) 2016-04-29 2019-06-24 Iomet Pharma Ltd Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
WO2017198159A1 (fr) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 Dérivé d'imidazole contenant un cycle de liaison
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11607426B2 (en) 2016-09-19 2023-03-21 University Of South Florida Method of targeting oncolytic viruses to tumors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
WO2018054365A1 (fr) * 2016-09-24 2018-03-29 Beigene, Ltd. Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
CN108203438B (zh) * 2016-12-20 2021-09-28 深圳微芯生物科技股份有限公司 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
CA3047002A1 (fr) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Nouveaux composes utiles en tant qu'inhibteurs de l'indoleamine 2,3-dioxygenase et/ou du tryptophane dioxygenase
EP3645533A1 (fr) 2017-06-28 2020-05-06 Genentech, Inc. Inhibiteurs de tdo2 et ido1
WO2019006047A1 (fr) 2017-06-28 2019-01-03 Genentech, Inc. Inhibiteurs de tdo2 et ido1
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JP6931067B2 (ja) * 2017-09-15 2021-09-01 大鵬薬品工業株式会社 Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤
JP7306634B2 (ja) * 2017-10-19 2023-07-11 一般社団法人ファルマバレープロジェクト支援機構 Ｉｄｏ／ｔｄｏ阻害剤
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
CN111587116A (zh) 2018-01-05 2020-08-25 迪克纳制药公司 降低β-连环蛋白和IDO表达以加强免疫疗法
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
WO2020018670A1 (fr) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Composés utiles en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase et/ou de la tryptophane dioxygénase
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
EP4052705A1 (fr) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions pour le traitement des maladies ou des pathologies associées à l'ebv
JP2024510949A (ja) 2021-03-05 2024-03-12 ウニヴェルシタット・バーゼル Ｅｂｖ関連疾患又は状態の治療用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (de) * 1967-08-15 1971-12-15 Sandoz Ag Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
WO2003087347A1 (fr) 2002-04-12 2003-10-23 Medical College Of Georgia Research Institute, Inc. Populations de cellules presentatrices de l'antigene et leur utilisation comme reactifs pour renforcer ou diminuer la tolerance immunitaire
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
EP2260846B1 (fr) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Nouveaux procédés pour le traitement du cancer
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
CA2932121A1 (fr) 2007-11-30 2009-06-11 Newlink Genetics Corporation Inhibiteurs de l'ido
CN102083429B (zh) 2008-04-24 2014-05-28 新联基因公司 Ido抑制剂
US8541595B2 (en) * 2008-11-13 2013-09-24 Merch Sharp & Dohme Corp. Imidazoisoindole neuropeptide S receptor antagonists
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
JP2012037986A (ja) 2010-08-04 2012-02-23 Canon Inc 画像形成装置及びその制御方法と画像形成システム
NO2694640T3 (fr) * 2011-04-15 2018-03-17

Also Published As

Publication number Publication date
RU2015143990A (ru) 2017-04-19
IL241027A0 (en) 2015-11-30
AU2014241079B2 (en) 2016-12-15
US9981973B2 (en) 2018-05-29
EP2976332A1 (fr) 2016-01-27
CL2016001940A1 (es) 2017-03-10
JP6093903B2 (ja) 2017-03-08
EP2976332B1 (fr) 2018-01-31
CA2902174A1 (fr) 2014-10-02
KR20150126623A (ko) 2015-11-12
AU2014241079C1 (en) 2017-07-06
US20160060266A1 (en) 2016-03-03
PH12015501866A1 (en) 2015-12-07
US9617272B2 (en) 2017-04-11
MA38493B1 (fr) 2017-10-31
AU2014241079B9 (en) 2017-04-06
BR112015022588A2 (pt) 2017-07-18
UA118103C2 (uk) 2018-11-26
RU2667509C2 (ru) 2018-09-21
HK1213259A1 (zh) 2016-06-30
JP2017052786A (ja) 2017-03-16
JP6352368B2 (ja) 2018-07-04
AU2014241079A1 (en) 2015-09-03
SG10201707545XA (en) 2017-10-30
WO2014159248A1 (fr) 2014-10-02
EP3366678A1 (fr) 2018-08-29
CR20150485A (es) 2015-11-26
PE20151593A1 (es) 2015-11-05
MX361375B (es) 2018-12-05
CN105189466A (zh) 2015-12-23
US20170260188A1 (en) 2017-09-14
AU2017201693A1 (en) 2017-03-30
SG11201507255QA (en) 2015-10-29
SA515361127B1 (ar) 2017-10-19
ZA201607948B (en) 2018-05-30
MX2015011385A (es) 2016-02-03
JP2016519056A (ja) 2016-06-30
CL2015002649A1 (es) 2016-07-29

Similar Documents

Publication Publication Date Title
MA38493B1 (fr) Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
MA38986B1 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
CY1117440T1 (el) Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido
MA38483A1 (fr) Inhibiteurs de l'ido
EA201790992A1 (ru) Иммунорегуляторные агенты
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
AR101177A1 (es) Inhibidores de la syk
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201892834A1 (ru) Комбинированная химиотерапия
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
MA48728B1 (fr) Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы